---
title: "Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285670697.md"
description: "Revolution Medicines, Inc. (RVMD) has highlighted risks associated with its warrants, which may dilute existing shareholders or become worthless if the share price falls below the exercise price before the December 2026 expiry. Investors must consider the potential for dilution against the uncertainty of the warrants retaining value. The average stock price target for RVMD is $176.95, indicating a 24.17% upside potential."
datetime: "2026-05-08T06:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285670697.md)
  - [en](https://longbridge.com/en/news/285670697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285670697.md)
---

# Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry

Revolution Medicines, Inc. (RVMD) has disclosed a new risk, in the Share Price & Shareholder Rights category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

From an external perspective, Revolution Medicines, Inc. faces warrant-related risks that could either dilute existing shareholders or leave warrant holders with securities that expire worthless. If the share price falls below the implied per-share exercise price before the December 2026 expiry, these warrants could lose all value, while remaining exercisable could introduce meaningful dilution.

Investors must weigh the uncertainty of the warrants staying in the money against the potential dilution that could occur if they are exercised in large volumes before expiration.

The average RVMD stock price target is $176.95, implying 24.17% upside potential.

To learn more about Revolution Medicines, Inc.’s risk factors, click here.

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md)
- [US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib](https://longbridge.com/en/news/286405546.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks](https://longbridge.com/en/news/286926662.md)
- [A Look At Revolution Medicines (RVMD) Valuation After Daraxonrasib Expanded Access Approval](https://longbridge.com/en/news/285222043.md)